Lv6
3100 积分 2021-10-18 加入
Development of potent inhibitors against KRAS, its mutant G12R, allosteric and Switch-I/Switch-II site
14小时前
已完结
Co-Targeting KRASG12D and the HER family is efficacious in colorectal cancer
1个月前
已完结
Targeting Innate Immune Checkpoint TREX1 is a Safe and Effective Immunotherapeutic Strategy in Cancer
1个月前
已完结
Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy
1个月前
已完结
Targeting PD-1+ T cells with small-format immunocytokines enhances IL-12 antitumor activity
1个月前
已完结
STING agonists drive recruitment and intrinsic type I interferon responses in monocytic lineage cells for optimal anti-tumor immunity
2个月前
已完结
Single-Agent Divarasib in Patients With KRAS G12C –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study
2个月前
已完结
Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia
2个月前
已关闭
Phase 1 and 2 Clinical Studies of the STING Agonist Ulevostinag With and Without Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors or Lymphomas
3个月前
已完结
SHP2 Allosteric Inhibitor SHP099 Alleviates Inflammation and Restores Salivary Gland Function in Sjögren's Disease-like Animals via Regulation of the IL-17RA Signaling Pathway
3个月前
已关闭
皖公网安备34019202002308
